MX2017000527A - Formulaciones de anticuerpos cristalinos. - Google Patents

Formulaciones de anticuerpos cristalinos.

Info

Publication number
MX2017000527A
MX2017000527A MX2017000527A MX2017000527A MX2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A MX 2017000527 A MX2017000527 A MX 2017000527A
Authority
MX
Mexico
Prior art keywords
antibody formulations
crystalline antibody
crystalline
formulations
antibody crystals
Prior art date
Application number
MX2017000527A
Other languages
English (en)
Spanish (es)
Inventor
Khalaf Nazer
MANDAPATI Saraswathi
J Patel Reena
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017000527A publication Critical patent/MX2017000527A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2017000527A 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos. MX2017000527A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024393P 2014-07-14 2014-07-14
PCT/US2015/040217 WO2016010927A1 (en) 2014-07-14 2015-07-13 Crystalline antibody formulations

Publications (1)

Publication Number Publication Date
MX2017000527A true MX2017000527A (es) 2017-08-10

Family

ID=53836192

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000527A MX2017000527A (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.

Country Status (7)

Country Link
US (2) US20170198059A1 (cg-RX-API-DMAC7.html)
EP (1) EP3169710A1 (cg-RX-API-DMAC7.html)
JP (3) JP2017525680A (cg-RX-API-DMAC7.html)
AU (2) AU2015289874A1 (cg-RX-API-DMAC7.html)
CA (1) CA2954767A1 (cg-RX-API-DMAC7.html)
MX (1) MX2017000527A (cg-RX-API-DMAC7.html)
WO (1) WO2016010927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525680A (ja) * 2014-07-14 2017-09-07 アムジェン インコーポレイテッド 結晶性抗体製剤
CA2954773C (en) 2014-07-14 2023-10-03 Amgen Inc. Crystalline antibody formulations
US20170056504A1 (en) * 2015-09-02 2017-03-02 Kenneth I. Kohn Method of extending half-life of crystaline antibodies
DK3596101T3 (da) 2017-03-14 2022-03-14 Amgen Inc Fremgangsmåder rettet mod krystallinske biomolekyler
WO2018200533A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
WO2018201064A1 (en) * 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
BR112020005959A2 (pt) * 2017-09-26 2020-10-06 Biocon Biologics India Limited filtração automatizada integrada para separação, lavagem e secagem de cristais de peptídeos
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503179A (ja) 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US8821086B2 (en) * 2006-12-22 2014-09-02 Tennine Corporation Method and apparatus for controlled-fracture machining
WO2008109871A2 (en) * 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
CA2681428A1 (en) * 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
US20130072665A1 (en) * 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009131740A2 (en) * 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
KR100985090B1 (ko) * 2008-05-23 2010-10-04 한국과학기술연구원 크라이센 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CA2777542A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2012101252A2 (en) * 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
US20140004122A1 (en) * 2011-05-10 2014-01-02 Amgen Inc. Methods for treating or preventing cholesterol related disorders
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
ITPN20110039A1 (it) * 2011-05-24 2012-11-25 Keyline S P A Blocchetto di presa perfezionato per macchina duplicatrice di chiavi
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2849788B1 (en) * 2012-05-17 2018-01-03 Cyon Therapeutics Inc. Proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors for use in treating sepsis and septic shock
CA2875096A1 (en) * 2012-06-15 2013-12-19 Genentech, Inc. Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
CA2906508A1 (en) * 2013-03-15 2014-09-25 Amgen, Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
AR095615A1 (es) * 2013-03-15 2015-10-28 Alder Biopharmaceuticals Inc Purificación de anticuerpos y monitoreo de pureza
EA201592267A1 (ru) * 2013-06-07 2016-04-29 Ридженерон Фармасьютикалз, Инк. Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
AU2013396206B2 (en) * 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
EA037526B1 (ru) * 2013-10-11 2021-04-08 Санофи Байотекнолоджи Применение ингибитора pcsk9 для лечения гиперлипидемии
EA201690889A1 (ru) * 2013-11-12 2016-11-30 Санофи Байотекнолоджи Режимы дозирования для применения ингибиторов pcsk9
US9034332B1 (en) * 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) * 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) * 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
CA2939507A1 (en) * 2014-02-14 2015-08-20 Regeneron Pharmaceuticals, Inc. Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
WO2015127273A1 (en) * 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9~glp-1 fusions and methods for use
CN106794244A (zh) * 2014-03-17 2017-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
CA2954773C (en) * 2014-07-14 2023-10-03 Amgen Inc. Crystalline antibody formulations
JP2017525680A (ja) * 2014-07-14 2017-09-07 アムジェン インコーポレイテッド 結晶性抗体製剤
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
EP3197492A1 (en) * 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
US11129936B2 (en) * 2016-04-08 2021-09-28 Amgen Inc. Drug delivery device, method of manufacture, and method of use
EP3448427A1 (en) * 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
US11059908B2 (en) * 2016-09-29 2021-07-13 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
US11459401B2 (en) * 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US20190031774A1 (en) * 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
EP4509527A3 (en) * 2017-10-18 2025-04-30 REGENXBIO Inc. Post-translationally modified fully human antibody therapeutic agents
JP7332691B2 (ja) * 2018-07-08 2023-08-23 スペシフィカ インコーポレイティド 抗体の開発可能性が最大化された抗体ライブラリー

Also Published As

Publication number Publication date
JP2018150337A (ja) 2018-09-27
US20170198059A1 (en) 2017-07-13
AU2021201422A1 (en) 2021-03-25
AU2015289874A1 (en) 2017-02-02
JP2017525680A (ja) 2017-09-07
CA2954767A1 (en) 2016-01-21
JP2020172526A (ja) 2020-10-22
EP3169710A1 (en) 2017-05-24
US11267902B2 (en) 2022-03-08
US20190127485A1 (en) 2019-05-02
WO2016010927A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
PH12016501894B1 (en) Anti-ox40 antibodies and methods of use
MY193661A (en) Anti-tim3 antibodies and methods of use
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MY176285A (en) Anti-fcrh5 antibodies
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
PH12016501763B1 (en) Multispecific antibodies
EP3461845A8 (en) Anti-cd33 antibodies and immunoconjugates
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2020012893A (es) Formulaciones de proteinas.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MY167350A (en) Fat-and-oil composition and chocolate
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
NZ721832A (en) Solid forms of tenofovir
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ744340A (en) Anti-jagged1 antibodies and methods of use